Famitinib：首次批准。

IF 14.4 1区医学 Q1 PHARMACOLOGY & PHARMACY

Drugs Pub Date : 2025-09-25 DOI:10.1007/s40265-025-02238-1

Susan J Keam

{"title":"Famitinib：首次批准。","authors":"Susan J Keam","doi":"10.1007/s40265-025-02238-1","DOIUrl":null,"url":null,"abstract":"Famitinib (®), an oral, multi-targeting tyrosine kinase inhibitor (TKI) with dual anti-tumour effects (inhibition of both cell proliferation and angiogenesis), is being developed by Jiangsu Hengrui Medicine Co., Ltd for the treatment of solid tumours. In May 2025, famitinib was granted conditional approval for use in combination with camrelizumab for the treatment of patients with recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy and have not received prior bevacizumab in China. This article summarizes the milestones in the development of famitinib leading to this first approval for the treatment of recurrent or metastatic cervical cancer.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":""},"PeriodicalIF":14.4000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Famitinib: First Approval.\",\"authors\":\"Susan J Keam\",\"doi\":\"10.1007/s40265-025-02238-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Famitinib (®), an oral, multi-targeting tyrosine kinase inhibitor (TKI) with dual anti-tumour effects (inhibition of both cell proliferation and angiogenesis), is being developed by Jiangsu Hengrui Medicine Co., Ltd for the treatment of solid tumours. In May 2025, famitinib was granted conditional approval for use in combination with camrelizumab for the treatment of patients with recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy and have not received prior bevacizumab in China. This article summarizes the milestones in the development of famitinib leading to this first approval for the treatment of recurrent or metastatic cervical cancer.\",\"PeriodicalId\":11482,\"journal\":{\"name\":\"Drugs\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":14.4000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40265-025-02238-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40265-025-02238-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

Famitinib（®）是一种口服多靶点酪氨酸激酶抑制剂（TKI），具有双重抗肿瘤作用（抑制细胞增殖和血管生成），由江苏恒瑞医药有限公司开发，用于治疗实体肿瘤。2025年5月，famitinib被有条件批准与camrelizumab联合用于治疗既往铂类化疗失败且既往未接受贝伐单抗的复发或转移性宫颈癌患者。本文总结了famitinib在治疗复发性或转移性宫颈癌中首次获批的里程碑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Famitinib: First Approval.

Famitinib (^®), an oral, multi-targeting tyrosine kinase inhibitor (TKI) with dual anti-tumour effects (inhibition of both cell proliferation and angiogenesis), is being developed by Jiangsu Hengrui Medicine Co., Ltd for the treatment of solid tumours. In May 2025, famitinib was granted conditional approval for use in combination with camrelizumab for the treatment of patients with recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy and have not received prior bevacizumab in China. This article summarizes the milestones in the development of famitinib leading to this first approval for the treatment of recurrent or metastatic cervical cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs 医学-毒理学

CiteScore

22.70

自引率

0.90%

发文量

134

审稿时长

3-8 weeks

期刊介绍： Drugs is a journal that aims to enhance pharmacotherapy by publishing review and original research articles on key aspects of clinical pharmacology and therapeutics. The journal includes: Leading/current opinion articles providing an overview of contentious or emerging issues. Definitive reviews of drugs and drug classes, and their place in disease management. Therapy in Practice articles including recommendations for specific clinical situations. High-quality, well designed, original clinical research. Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs. AdisInsight Reports summarising development at first global approval. Moreover, the journal offers additional digital features such as animated abstracts, video abstracts, instructional videos, and podcasts to increase visibility and educational value. Plain language summaries accompany articles to assist readers with some knowledge of the field in understanding important medical advances.